Iovance Biotherapeutics, Inc.

303 articles about Iovance Biotherapeutics, Inc.

• CEO of Bay Area’s Iovance Biotherapeutics Sees TIL Technology as Best Immunotherapy Option for Treating Solid Tumors

  9/7/2017

• Iovance Biotherapeutics Announces FDA Fast Track Designation For LN-144 For Treatment Of Advanced Melanoma

  9/1/2017

• Iovance Biotherapeutics Announces First Patient Dosed In C-145-04 Phase II Trial In Cervical Cancer

  8/16/2017

• Iovance Biotherapeutics Appoints Timothy Morris As Chief Financial Officer

  8/9/2017

• Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results

  8/2/2017

• Iovance Biotherapeutics To Host Conference Call To Discuss Second Quarter 2017 Financial And Operating Results On Tuesday, August 1, 2017

  7/25/2017

• Lion Biotech Changes Name To Iovance Biotherapeutics, Inc.

  6/28/2017

• Lion Biotech Announces Strategic Alliance With MD Anderson Cancer Center To Conduct Clinical Trials Of Tils In Multiple Solid Tumors

  4/20/2017

• Lion Biotech Presents Encouraging Til Technology Data In Four Posters At 2016 SITC Annual Meeting

  11/8/2016

• Lion Biotech Announces Presentations At Upcoming SITC 31st Annual Meeting

  10/26/2016

• TroyGould Closes $100 Million Lion Biotech Deal

  6/15/2016

• Lion Biotech Raises Approximately $100 Million and Names a New CEO

  6/7/2016

• Lion Biotech Names Steven A. Fischkoff Chief Medical Officer

  2/4/2016

• Lion Biotech Submits Investigational New Drug Application To Conduct Studies In Cervical, Head And Neck Cancer

  1/4/2016

• Lion Biotech Announces Selection For Addition To NASDAQ Biotechnology Index

  12/15/2015

• Lion Biotech To Participate In Upcoming Investor Conferences

  11/16/2015

• Lion Biotech Announces Agreement With WuXi AppTec, Inc. To Increase TIL Manufacturing Capacity

  11/9/2015

• Lion Biotech Announces Third Quarter 2015 Financial Results

  11/5/2015

• Lion Biotech Announces The Departure Of Dr. Laszlo Radvanyi

  11/2/2015

• Lion Biotechnologies, Inc. Obtains Exclusive License From NIH To Develop And Commercialize TIL In Bladder, Lung, Breast And HPV-Associated Cancers

  10/7/2015